| Literature DB >> 21308974 |
Timothy H Montague1, Diane Potvin, Charles E Diliberti, Walter W Hauck, Alan F Parr, Donald J Schuirmann.
Abstract
In 2008, this group published a paper on approaches for two-stage crossover bioequivalence (BE) studies that allowed for the reestimation of the second-stage sample size based on the variance estimated from the first-stage results. The sequential methods considered used an assumed GMR of 0.95 as part of the method for determining power and sample size. This note adds results for an assumed GMR = 0.90. Two of the methods recommended for GMR = 0.95 in the earlier paper have some unacceptable increases in Type I error rate when the GMR is changed to 0.90. If a sponsor wants to assume 0.90 for the GMR, Method D is recommended.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21308974 DOI: 10.1002/pst.483
Source DB: PubMed Journal: Pharm Stat ISSN: 1539-1604 Impact factor: 1.894